Key result
The ANGPTL4 E40K variant (GA genotype) was associated with a decreased risk of cardiovascular disease (OR 0.74) and lower fasting triglyceride levels in Tunisian patients with type 2 diabetes.
Why the study?
Do ANGPTL4 variants E40K and T266M associate with lower fasting triglyceride levels and reduced cardiovascular disease risk in a Type 2 diabetic Tunisian population?
Case-Control (n=220)
No
Do ANGPTL4 variants E40K and T266M associate with lower fasting triglyceride levels and reduced cardiovascular disease risk in a Type 2 diabetic Tunisian population?
Odds Ratio: 0.74 (95% CI 0.54–1.65)
p-value: p=0.01
ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels and a decreased cardiovascular risk in Type 2 diabetic Tunisian patients.
Should not yet change T2D management; extends ANGPTL4 associations to this population but remains hypothesis-generating.
BACKGROUND: Angiopoietin-like protein 4 (ANGPTL4) is a metabolic factor that increases plasma triglyceride levels by inhibiting lipoprotein lipase (LPL). The objective of this study was to investigate the association of ANGPTL4 variants (E40K and T266M) with triglyceride levels and with cardiovascular risk factors, such as metabolic syndrome (MetS) and obesity in type 2 diabetic Tunisian population. METHODS: We investigated the effect of the tagging single nucleotide polymorphisms (SNPs) rs1044250 (T266M) and rs116843064 (E40K) with triglyceride (TG) levels and CAD risk factors in a cohort of 220 patients undergoing coronary angiography for the evaluation of stable CAD, all of whom had (type 2 diabetes) T2D and were at least overweight. Multivariate logistic regressions were performed on association studies. RESULTS: TT genotype of rs1044250 (T266M variant) showed a protective effect on CVD risk in CAD group patients (OR 1.92, 95% CI 0.601.42, p =0.05) compared with control Group patients (OR 1.17, 95% CI 0.70-1.66, p = 0.72). Likewise, GA genotype of rs116843064 (E40K variant): (OR 0.74, 95% CI 0.54-1.65, p =0.01) for the CAD group compared with control Group patients (OR 1.12, 95% CI 0.68-1.74, p = 0.074). CONCLUSIONS: ANGPTL4 variants are associated with, not only lower fasting triglyceride levels, but also a decreased cardiovascular risk in T2D Tunisian patients. So, T266M and E40K polymorphism predicts cardiovascular disease risk in Type 2 diabetic Tunisian population.
No takes yet. Share an insight, caveat, or question.
Abid et al. (2016) conducted a case-control in Type 2 diabetes and coronary artery disease (n=220). ANGPTL4 variants E40K and T266M vs. Wild-type genotypes was evaluated on Cardiovascular disease risk (presence of CAD) (OR 0.74, 95% CI 0.54-1.65, p=0.01). The ANGPTL4 E40K variant (GA genotype) was associated with a decreased risk of cardiovascular disease (OR 0.74) and lower fasting triglyceride levels in Tunisian patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: